Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: UBE2W

Gene summary for UBE2W

Gene summary.

Gene information	Species	Human
	Gene symbol	UBE2W
	Gene ID	55284
	Gene name	ubiquitin conjugating enzyme E2 W
	Gene Alias	UBC-16
	Cytomap	8q21.11
	Gene Type	protein-coding
	GO ID	GO:0000209
	UniProtAcc	Q96B02

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
55284	UBE2W	LZE4T	Human	Esophagus	ESCC	2.35e-20	6.53e-01	0.0811
55284	UBE2W	LZE7T	Human	Esophagus	ESCC	1.60e-07	2.77e-01	0.0667
55284	UBE2W	LZE8T	Human	Esophagus	ESCC	6.74e-03	1.95e-01	0.067
55284	UBE2W	LZE20T	Human	Esophagus	ESCC	1.73e-06	3.18e-01	0.0662
55284	UBE2W	LZE22T	Human	Esophagus	ESCC	2.37e-02	2.18e-01	0.068
55284	UBE2W	LZE24T	Human	Esophagus	ESCC	5.50e-18	5.18e-01	0.0596
55284	UBE2W	LZE6T	Human	Esophagus	ESCC	9.78e-08	2.92e-01	0.0845
55284	UBE2W	P1T-E	Human	Esophagus	ESCC	2.80e-02	2.05e-01	0.0875
55284	UBE2W	P2T-E	Human	Esophagus	ESCC	7.38e-12	1.38e-01	0.1177
55284	UBE2W	P4T-E	Human	Esophagus	ESCC	3.10e-19	3.30e-01	0.1323
55284	UBE2W	P5T-E	Human	Esophagus	ESCC	4.15e-13	2.49e-01	0.1327
55284	UBE2W	P8T-E	Human	Esophagus	ESCC	3.65e-13	2.17e-01	0.0889
55284	UBE2W	P9T-E	Human	Esophagus	ESCC	2.08e-04	1.81e-01	0.1131
55284	UBE2W	P10T-E	Human	Esophagus	ESCC	4.09e-15	2.97e-01	0.116
55284	UBE2W	P11T-E	Human	Esophagus	ESCC	6.15e-08	3.12e-01	0.1426
55284	UBE2W	P12T-E	Human	Esophagus	ESCC	9.06e-11	3.06e-01	0.1122
55284	UBE2W	P15T-E	Human	Esophagus	ESCC	9.19e-09	2.04e-01	0.1149
55284	UBE2W	P16T-E	Human	Esophagus	ESCC	3.24e-19	4.06e-01	0.1153
55284	UBE2W	P20T-E	Human	Esophagus	ESCC	5.37e-12	2.12e-01	0.1124
55284	UBE2W	P21T-E	Human	Esophagus	ESCC	1.29e-17	3.81e-01	0.1617

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0010498111	Esophagus	ESCC	proteasomal protein catabolic process	369/8552	490/18723	1.13e-41	1.80e-38	369
GO:0043161111	Esophagus	ESCC	proteasome-mediated ubiquitin-dependent protein catabolic process	312/8552	412/18723	3.53e-36	4.48e-33	312
GO:0035966111	Esophagus	ESCC	response to topologically incorrect protein	125/8552	159/18723	1.44e-17	1.27e-15	125
GO:000020917	Esophagus	ESCC	protein polyubiquitination	170/8552	236/18723	1.40e-16	1.09e-14	170
GO:0035967111	Esophagus	ESCC	cellular response to topologically incorrect protein	90/8552	116/18723	1.94e-12	8.11e-11	90
GO:00065136	Esophagus	ESCC	protein monoubiquitination	53/8552	67/18723	2.11e-08	4.03e-07	53
GO:007097912	Esophagus	ESCC	protein K11-linked ubiquitination	27/8552	29/18723	8.09e-08	1.39e-06	27
GO:00517884	Esophagus	ESCC	response to misfolded protein	21/8552	25/18723	9.12e-05	6.54e-04	21
GO:00712184	Esophagus	ESCC	cellular response to misfolded protein	19/8552	23/18723	3.12e-04	1.85e-03	19
GO:00065154	Esophagus	ESCC	protein quality control for misfolded or incompletely synthesized proteins	21/8552	28/18723	1.57e-03	7.33e-03	21
GO:001049812	Liver	Cirrhotic	proteasomal protein catabolic process	216/4634	490/18723	2.52e-21	9.29e-19	216
GO:004316112	Liver	Cirrhotic	proteasome-mediated ubiquitin-dependent protein catabolic process	184/4634	412/18723	4.52e-19	8.85e-17	184
GO:00359667	Liver	Cirrhotic	response to topologically incorrect protein	91/4634	159/18723	2.07e-18	3.60e-16	91
GO:00359677	Liver	Cirrhotic	cellular response to topologically incorrect protein	64/4634	116/18723	2.20e-12	1.62e-10	64
GO:000020911	Liver	Cirrhotic	protein polyubiquitination	89/4634	236/18723	6.09e-06	9.80e-05	89
GO:000651511	Liver	Cirrhotic	protein quality control for misfolded or incompletely synthesized proteins	16/4634	28/18723	2.53e-04	2.27e-03	16
GO:0070979	Liver	Cirrhotic	protein K11-linked ubiquitination	16/4634	29/18723	4.36e-04	3.55e-03	16
GO:00517881	Liver	Cirrhotic	response to misfolded protein	14/4634	25/18723	8.15e-04	5.95e-03	14
GO:00712182	Liver	Cirrhotic	cellular response to misfolded protein	12/4634	23/18723	4.23e-03	2.24e-02	12
GO:00065133	Liver	Cirrhotic	protein monoubiquitination	26/4634	67/18723	7.53e-03	3.57e-02	26

Page: 1 2 3 4

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0412027	Esophagus	ESCC	Ubiquitin mediated proteolysis	122/4205	142/8465	6.53e-20	7.29e-18	3.74e-18	122
hsa0412036	Esophagus	ESCC	Ubiquitin mediated proteolysis	122/4205	142/8465	6.53e-20	7.29e-18	3.74e-18	122
hsa0412021	Liver	Cirrhotic	Ubiquitin mediated proteolysis	72/2530	142/8465	1.32e-07	1.97e-06	1.21e-06	72
hsa0412031	Liver	Cirrhotic	Ubiquitin mediated proteolysis	72/2530	142/8465	1.32e-07	1.97e-06	1.21e-06	72
hsa0412041	Liver	HCC	Ubiquitin mediated proteolysis	110/4020	142/8465	1.67e-13	3.74e-12	2.08e-12	110
hsa0412051	Liver	HCC	Ubiquitin mediated proteolysis	110/4020	142/8465	1.67e-13	3.74e-12	2.08e-12	110
hsa0412020	Oral cavity	OSCC	Ubiquitin mediated proteolysis	105/3704	142/8465	1.83e-13	4.37e-12	2.23e-12	105
hsa04120110	Oral cavity	OSCC	Ubiquitin mediated proteolysis	105/3704	142/8465	1.83e-13	4.37e-12	2.23e-12	105
hsa0412043	Oral cavity	EOLP	Ubiquitin mediated proteolysis	48/1218	142/8465	3.55e-09	6.74e-08	3.98e-08	48
hsa0412053	Oral cavity	EOLP	Ubiquitin mediated proteolysis	48/1218	142/8465	3.55e-09	6.74e-08	3.98e-08	48

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

UBE2W

SNV

Missense_Mutation

c.491N>A

p.Arg164Gln

p.R164Q

protein_coding

deleterious(0.03)

benign(0.111)

TCGA-A2-A1FV-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cyclophosphamide

UBE2W

SNV

Missense_Mutation

novel

c.28G>C

p.Ala10Pro

p.A10P

protein_coding

tolerated_low_confidence(0.26)

benign(0.44)

TCGA-EX-A1H6-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

UBE2W

SNV

Missense_Mutation

novel

c.361C>T

p.His121Tyr

p.H121Y

protein_coding

deleterious(0.04)

possibly_damaging(0.517)

TCGA-VS-A9UC-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

UBE2W

SNV

Missense_Mutation

rs775096274

c.497C>T

p.Pro166Leu

p.P166L

protein_coding

deleterious(0.03)

possibly_damaging(0.846)

TCGA-A6-6781-01

Colorectum

colon adenocarcinoma

Male

<65

III/IV

Chemotherapy

oxaliplatin

UBE2W

SNV

Missense_Mutation

novel

c.216N>G

p.Asn72Lys

p.N72K

protein_coding

tolerated(0.07)

benign(0.063)

TCGA-F5-6814-01

Colorectum

rectum adenocarcinoma

Male

<65

I/II

Unknown

UBE2W

SNV

Missense_Mutation

novel

c.227A>C

p.Gln76Pro

p.Q76P

protein_coding

deleterious(0.03)

possibly_damaging(0.668)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

UBE2W

SNV

Missense_Mutation

novel

c.206G>A

p.Ser69Asn

p.S69N

protein_coding

tolerated(0.14)

benign(0.012)

TCGA-A5-A1OF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

UBE2W

SNV

Missense_Mutation

novel

c.475T>C

p.Cys159Arg

p.C159R

protein_coding

deleterious(0)

probably_damaging(0.913)

TCGA-A5-A2K5-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

UBE2W

SNV

Missense_Mutation

c.189N>T

p.Met63Ile

p.M63I

protein_coding

tolerated(0.88)

benign(0.012)

TCGA-AP-A056-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

UBE2W

SNV

Missense_Mutation

c.506N>A

p.Ser169Tyr

p.S169Y

protein_coding

deleterious(0.01)

possibly_damaging(0.847)

TCGA-AX-A05Z-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

Page: 1 2 3

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1